Denali and Royalty Pharma Strike $275M Deal for Hunter Syndrome Treatment

Denali Therapeutics secures $275 million from Royalty Pharma for tividenofusp alfa, a promising therapy for Hunter syndrome awaiting FDA approval in April 2026.